ACM
PTGX icon

Altium Capital Management’s Protagonist Therapeutics PTGX Stock Holding History

Altium Capital Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-365,100
Closed -$2.89M – 151
2022
Q2 		$2.89M Buy
365,100
+360,100
+7,202% +$4.35M 1.16% 32
2022
Q1 		$11.8M Buy
+5,000
New +$141K 3.96% 1

Other funds holding PTGX

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Altium Capital Management's PTGX Position: Q2 2022 in Review

Altium Capital Management sold out of Protagonist Therapeutics (PTGX) in Q2 2022, closing a stake of 386,000 shares — an estimated $4.67M sold.

Altium Capital Management first reported a position in PTGX in Q4 2020 and held it in 6 quarters. The position peaked at $12.7M in Q2 2021. 130 funds tracked by Wall St. Rank hold PTGX as of Q2 2022.

  • Altium Capital Management reported no remaining Protagonist Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Altium Capital Management sold 386,000 Protagonist Therapeutics shares in Q2 2022, an estimated $4.67M.
  • Altium Capital Management first reported a position in Protagonist Therapeutics in Q4 2020 and held it in 6 quarters.
  • Altium Capital Management's Protagonist Therapeutics position peaked at $12.7M in Q2 2021.
  • 130 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2022.

Based on Altium Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.